Fairmount Partners Advises EastHORN Clinical Services in its Acquisition by Novotech

Sydney, Australia – January 10, 2023 – Novotech, the leading Asia-Pacific biotech specialist CRO, announced today the acquisition of EastHORN Clinical Services (“EastHORN”), a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent. The acquisition is part of Novotech’s global expansion program. EastHORN was established in 2004 and has over 250 employees.

The acquisition means biotech clients can access Novotech’s unique and unparalleled suite of early to late-phase CRO services across Europe and the US, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.

Novotech CEO Dr. John Moller said: “This acquisition is a strategic move to further expand our CRO operations and provide biotech clients with in-country expertise across Asia-Pacific, North America, and Europe to deliver their global drug development programs. EastHORN and Novotech have been working together for many years and we share a culture of clinical excellence in biotech drug development. EastHORN which is retaining its brand, is now a Novotech company and will be integrated into our systems and processes so clients benefit from working with one CRO globally. Clients can now access our exceptional European infrastructure, local knowledge. site relationships and access to diverse patient populations.”

EastHORN Executive Chairman Iain Gordon said: “I first started working on clinical projects with Novotech 15 years ago and have always been impressed by the quality of their services and their client-focused approach. EastHORN has been working closely with Novotech for over a decade now and have many friends within the Novotech team. This is a natural next step for our group and my colleagues and I are excited to become part of Novotech’s global operations to support biotech clients’ clinical programs. In particular, we can now offer our clients access to Novotech’s team of experts across Asia-Pacific and the US including project management, regulatory, clinical, medical and biometrics, while our team’s European expertise can advance clinical development in Europe for Novotech clients. We work with similar-sized biotechs and small to mid-size pharma companies and have experience across the same therapeutic areas, so this is an excellent cultural and strategic fit.”

Novotech has decades of biotech drug development experience, exceptional site and investigator relationships, access to vast patient populations, and a project management approach focused on problem-solving, ownership and flexibility. Consistent investment in advanced training and technology combines to deliver an exceptional full-service biotech CRO solution.

Novotech has recently been recognized with significant CRO awards including the Asia-Pacific Biotech CRO of the Year by Frost & Sullivan, benchmarked as a top 10 CRO among the world’s leading CROs, a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award.

In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.

Fairmount Partners, a leading investment bank in the Pharmaceutical Services sector, served as exclusive financial advisor to EastHORN.

About Novotech

Novotech (www.novotech-cro.com) is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US.

About EastHORN

EastHORN (www.easthorn.com) is one of the leading full-service CROs in Europe, operating in over 30 countries in the region with an experienced staff largely comprised of physicians and PhDs. EastHORN professionals have been engaged in Phase I-IV clinical trial studies in Europe and globally and cover most major therapeutic areas, including, among others, oncology, cardiology, gastroenterology, immunology, ophthalmology, rheumatology, nephrology, metabolic, CNS, women’s health disorders and pediatric indications. EastHORN serves a broad range of clients, from the largest global pharmaceutical companies to the smallest virtual biotechs.

About Fairmount Partners

Fairmount Partners (www.fairmountpartners.com) is an independent merger and acquisition advisory firm focused on emerging growth and middle-market companies.  Fairmount helps its clients complete mergers and acquisitions, raise funds for growth, acquisitions and liquidity, and design and improve their corporate development strategies.  Fairmount’s clients include successful entrepreneurs, private equity-sponsored enterprises, and global public companies.  Since 2003, Fairmount has completed more than 270 transactions, representing over $15 billion in aggregate value, in 22 countries throughout North and South America, Europe, Asia and Australia.  For further information, please contact:

Neal McCarthy

Managing Director

(610) 260-6224